What is Jasper Therapeutics, Inc.'s earnings per share (EPS)?

Jasper Therapeutics, Inc. (JSPR) reported diluted earnings per share of -$3.95 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jasper Therapeutics, Inc. (JSPR) Financials

JSPR

FY2025 annual

Revenue Not reported for FY2025

Net Income -$76 +100.0% YoY

EPS (Diluted) -$3.95 YoY not available

Operating Cash Flow -$77.2M -23.3% YoY

Market Cap $19.7M as of Oct 5, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 14.0x on $1.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JSPR SEC filings page.

This page shows Jasper Therapeutics, Inc. (JSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI JSPR FY2025 2026-10-03

Jasper operates as a research-funded development business: cash outflows are widening while equity has become thin.

Operating loss widened from $76.2M in FY2024 to $83.9M in FY2025, while operating cash outflow also deepened. That alignment indicates the deterioration reflects real cash consumption, not merely accounting charges.

With no reported revenue, research and development is the operating engine: spending rose from $55.8M to $63.1M across the latest two years. The business is therefore funding development before demonstrating a sales-based cash cycle.

By FY2025, $31.6M of liabilities stood against only $4.2M of equity, leaving a narrow capital cushion. External financing supplied $34.2M, while the supplied liquidity comparison equaled 4.5 months of reported outflow.

Financial Health Signals

Financial health score not available

Jasper Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Jasper Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Jasper Therapeutics, Inc. reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

$11.8M

YoY+144.0%

QoQ+207.9%

Jasper Therapeutics, Inc.'s EBITDA was $11.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 144.0% from the same quarter a year earlier. Against the prior quarter it is up 207.9%.

Net Income

-$2.8M

YoY+89.7%

QoQ-135.1%

Jasper Therapeutics, Inc. reported -$2.8M in net income in Q2 2026. This represents an increase of 89.7% from the same quarter a year earlier. Against the prior quarter it is down 135.1%.

EPS (Diluted)

-$0.10

QoQ-150.0%

Jasper Therapeutics, Inc. earned -$0.10 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 150.0%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$7.3M

YoY-81.5%

QoQ-48.3%

5Y CAGR+88.2%

Jasper Therapeutics, Inc. held $7.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

33M

QoQ+18.9%

Jasper Therapeutics, Inc. had 33M shares outstanding in Q2 2026. Against the prior quarter it is up 18.9%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-195.3%

YoY-81.6pp

QoQ-160.8pp

Jasper Therapeutics, Inc.'s ROE was -195.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 81.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 160.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$5.1M

YoY-75.8%

QoQ-11.7%

Jasper Therapeutics, Inc. invested $5.1M in research and development in Q2 2026. This represents a decrease of 75.8% from the same quarter a year earlier. Against the prior quarter it is down 11.7%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

JSPR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JSPR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Cost of Revenue	N/A	$41.6M+21.5%	$34.3M	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$63.1M+13.0%	$55.8M+7.8%	$51.8M+49.6%	$34.6M+36.2%	$25.4M+60.1%	$15.9M
SG&A Expenses	N/A	$20.8M+1.8%	$20.4M+19.6%	$17.1M+3.1%	$16.6M+45.2%	$11.4M+137.8%	$4.8M
Operating Income	N/A	-$83.9M-10.0%	-$76.2M-10.7%	-$68.9M-34.5%	-$51.2M-39.0%	-$36.8M-78.1%	-$20.7M
EBITDA	N/A	-$82.8M-10.6%	-$74.9M-10.5%	-$67.8M-34.9%	-$50.2M-37.8%	-$36.5M	N/A
Interest Expense	N/A	N/A	N/A	-$246K-113.9%	-$115K-43.8%	-$80K+27.9%	-$111K
Income Tax	N/A	N/A	$2K0.0%	$2K	N/A	N/A	$38K
Net Income	N/A	-$76+100.0%	-$71.3M-10.5%	-$64.5M-71.2%	-$37.7M-23.0%	-$30.6M+3.3%	-$31.7M
EPS (Basic)	N/A	-$3.95+19.2%	-$4.89+20.9%	-$6.18+40.2%	-$10.33-284.0%	-$2.69	N/A
EPS (Diluted)	-$1.04	-$3.95	-$4.89+20.9%	-$6.18	-$10.33	-$2.69	N/A
Diluted Shares (Avg)	N/A	19M	15M+39.7%	10M	4M	11M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Cost of Revenue	$3.6M-77.3%	$3.6M-62.9%	N/A	$9.3M+6.4%	$15.8M	$9.8M	N/A	$8.8M
R&D Expenses	$5.1M-75.8%	$5.8M-64.0%	N/A	$14.4M-0.4%	$21.2M+87.6%	$16.2M+56.9%	N/A	$14.5M-2.6%
SG&A Expenses	$4.1M-30.7%	$5.1M-9.0%	N/A	$4.8M-12.1%	$5.9M+25.2%	$5.6M+18.2%	N/A	$5.4M+20.4%
Operating Income	-$9.2M+66.0%	-$11.0M+49.8%	N/A	-$19.2M+3.6%	-$27.1M-69.3%	-$21.8M-44.7%	N/A	-$19.9M-2.7%
EBITDA	$11.8M+144.0%	-$10.9M+49.2%	N/A	-$18.9M+2.3%	-$26.8M-70.6%	-$21.5M-45.6%	N/A	-$19.4M-1.7%
Net Income	-$2.8M+89.7%	-$1.2M+94.5%	N/A	-$18.7M-0.5%	-$26.7M-83.2%	-$21.2M-54.7%	N/A	-$18.6M-6.2%
EPS (Basic)	-$0.10+94.3%	-$0.04+97.2%	$0.23+114.0%	-$1.13+8.9%	-$1.74-79.4%	-$1.41-36.9%	-$1.64-9.3%	-$1.24+22.5%
EPS (Diluted)	-$0.10	-$0.04	$0.23	-$1.13	-$1.74-79.4%	-$1.41-36.9%	-$1.64-9.3%	-$1.24
Diluted Shares (Avg)	29M	29M	N/A	17M	15M+2.3%	15M+12.7%	N/A	15M

Not reported in any period shown, so not listed: Revenue, Gross Profit, Interest Expense, Income Tax.

JSPR Balance Sheet

JSPR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$35.8M-55.2%	$79.9M-15.8%	$94.9M+96.2%	$48.4M-48.4%	$93.7M+301.0%	$23.4M
Current Assets	$34.6M-54.3%	$75.8M-14.8%	$88.9M+113.1%	$41.7M-52.5%	$87.8M+324.6%	$20.7M
Cash & Equivalents	$28.7M-59.9%	$71.6M-17.6%	$86.9M+127.2%	$38.3M-54.8%	$84.7M+327.0%	$19.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$31.6M+73.5%	$18.2M+10.8%	$16.5M+33.0%	$12.4M-48.7%	$24.1M-58.7%	$58.5M
Current Liabilities	$13.2M-13.4%	$15.2M+23.1%	$12.4M+75.1%	$7.1M-11.9%	$8.0M+99.9%	$4.0M
Non-Current Liabilities	$18.4M+516.7%	$3.0M-26.7%	$4.1M-23.2%	$5.3M-67.1%	$16.1M-70.4%	$54.5M
Total Equity	$4.2M-93.3%	$61.7M-21.4%	$78.4M+118.0%	$36.0M-48.2%	$69.5M+297.9%	-$35.1M
Retained Earnings	-$316.7M-31.5%	-$240.9M-42.0%	-$169.6M-61.3%	-$105.1M-55.9%	-$67.5M-83.2%	-$36.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$11.8M-74.6%	$21.2M-63.2%	$35.8M-55.2%	$57.5M-42.2%	$46.5M-59.2%	$57.6M-54.3%	$79.9M-15.8%	$99.4M-10.0%
Current Assets	$11.6M-73.1%	$20.3M-61.8%	$34.6M-54.3%	$54.6M-42.4%	$43.0M-60.5%	$53.2M-55.8%	$75.8M-14.8%	$94.8M-9.9%
Cash & Equivalents	$7.3M-81.5%	$14.1M-71.0%	$28.7M-59.9%	$50.9M-45.0%	$39.5M-63.0%	$48.8M-58.8%	$71.6M-17.6%	$92.5M-10.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.4M-54.8%	$17.8M+15.8%	$31.6M+73.5%	$45.9M+191.7%	$23.0M+68.6%	$15.4M+20.6%	$18.2M+10.8%	$15.7M-3.3%
Current Liabilities	$7.8M-61.7%	$9.0M-27.1%	$13.2M-13.4%	$21.0M+68.9%	$20.5M+103.6%	$12.3M+38.3%	$15.2M+23.1%	$12.5M+4.6%
Non-Current Liabilities	$2.5M+3.2%	$8.8M+191.1%	$18.4M+516.7%	$24.9M+659.2%	$2.5M-30.6%	$3.0M-20.9%	$3.0M-26.7%	$3.3M-25.0%
Total Equity	$1.4M-94.0%	$3.4M-92.0%	$4.2M-93.3%	$11.6M-86.2%	$23.5M-76.6%	$42.2M-62.7%	$61.7M-21.4%	$83.7M-11.1%
Retained Earnings	-$320.6M-11.0%	-$317.8M-21.3%	-$316.7M-31.5%	-$307.6M-42.0%	-$288.8M-45.9%	-$262.1M-43.0%	-$240.9M-42.0%	-$216.5M-41.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

JSPR Cash Flow Statement

JSPR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$60.3M	-$77.2M-23.3%	-$62.6M-20.2%	-$52.1M-13.5%	-$45.9M-36.2%	-$33.7M-84.4%	-$18.3M
Depreciation & Amortization	N/A	$1.1M-23.1%	$1.4M+23.9%	$1.1M+13.6%	$975K+158.6%	$377K	N/A
Stock-Based Compensation	N/A	$6.7M+1.4%	$6.6M+27.0%	$5.2M+27.4%	$4.1M+290.4%	$1.0M-13.4%	$1.2M
Investing Cash Flow	N/A	$5K+100.9%	-$532K-99.3%	-$267K+53.6%	-$576K+76.3%	-$2.4M-1324.1%	$198K
Financing Cash Flow	N/A	$34.2M-28.6%	$47.9M-52.6%	$101.0M+183483.6%	$55K-99.9%	$101.0M+794.6%	$11.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$6.9M+55.2%	-$14.5M+36.3%	-$21.9M-3.5%	-$17.0M-21.0%	-$15.5M-32.3%	-$22.8M-45.2%	-$21.1M-28.2%	-$14.1M-17.3%
Depreciation & Amortization	$21.0M+6900.0%	$21K-92.5%	$290K+18.4%	$229K-54.2%	$300K0.0%	$279K-3.1%	$245K	$500K+66.7%
Stock-Based Compensation	N/A	$423K-76.6%	N/A	$1.4M-28.7%	$1.8M+22.6%	$1.8M+54.9%	N/A	$2.0M+43.2%
Investing Cash Flow	N/A	N/A	$0+100.0%	$0+100.0%	$1K+100.6%	$4K+116.0%	-$76K+67.0%	-$274K
Financing Cash Flow	N/A	N/A	-$340K-198.6%	$28.4M+315322.2%	N/A	N/A	$345K+227.3%	$9K-75.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

JSPR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JSPR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Return on Equity	0.0%+115.6pp	-115.6%-33.4pp	-82.2%+22.5pp	-104.7%-60.6pp	-44.1%	N/A
Return on Assets	0.0%+89.2pp	-89.2%-21.3pp	-68.0%+10.0pp	-77.9%-45.2pp	-32.7%+102.9pp	-135.6%
Current Ratio	2.62-2.4x	4.98-2.2x	7.19+1.3x	5.91-5.0x	10.95+5.8x	5.16
Debt-to-Equity	7.62+7.3x	0.30+0.1x	0.21-0.1x	0.340.0x	0.35	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-195.3%-81.6pp	-34.5%+15.8pp	N/A	-161.9%-139.7pp	-113.7%-99.2pp	-50.3%-38.2pp	N/A	-22.3%-3.6pp
Return on Assets	-23.4%+34.1pp	-5.5%+31.3pp	N/A	-32.6%-13.9pp	-57.5%-44.7pp	-36.9%-26.0pp	N/A	-18.8%-2.9pp
Current Ratio	1.48-0.6x	2.26-2.1x	2.62-2.4x	2.59-5.0x	2.10-8.7x	4.31-9.2x	4.98-2.2x	7.61-1.2x
Debt-to-Equity	7.35+6.4x	5.23+4.9x	7.62+7.3x	3.97+3.8x	0.98+0.8x	0.36+0.3x	0.30+0.1x	0.190.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Jasper Therapeutics, Inc. JSPR	FY2025	N/A	-$76	N/A	$19.7M	—
LAVA Therapeutics N.V. LVTX	FY2024	$12.0M	-$25.1M	N/A	$45.8M	53/100
Estrella Immunopharma, Inc. ESLA	FY2025	N/A	-$13.1M	N/A	$20.4M	—
PepGen Inc. PEPG	FY2025	N/A	-$89.7M	N/A	$157.9M	—
Lantern Pharma Inc. LTRN	FY2025	N/A	-$17.1M	N/A	$12.8M	—
Klotho Neurosciences, Inc. KLTO	FY2025	N/A	-$10.6M	N/A	$56.7M	—

Where Jasper Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Jasper Therapeutics, Inc. profitable?

No, Jasper Therapeutics, Inc. (JSPR) reported a net income of -$76 in fiscal year 2025.

What is Jasper Therapeutics, Inc.'s EBITDA?

Jasper Therapeutics, Inc. (JSPR) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jasper Therapeutics, Inc.'s return on equity (ROE)?

Jasper Therapeutics, Inc. (JSPR) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Jasper Therapeutics, Inc.'s operating cash flow?

Jasper Therapeutics, Inc. (JSPR) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Jasper Therapeutics, Inc.'s total assets?

Jasper Therapeutics, Inc. (JSPR) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Jasper Therapeutics, Inc. spend on research and development?

Jasper Therapeutics, Inc. (JSPR) invested $63.1M in research and development during fiscal year 2025.

How many shares does Jasper Therapeutics, Inc. have outstanding?

Jasper Therapeutics, Inc. (JSPR) had 28M shares outstanding as of fiscal year 2025.

What is Jasper Therapeutics, Inc.'s current ratio?

Jasper Therapeutics, Inc. (JSPR) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.

What is Jasper Therapeutics, Inc.'s debt-to-equity ratio?

Jasper Therapeutics, Inc. (JSPR) had a debt-to-equity ratio of 7.62 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jasper Therapeutics, Inc.'s return on assets (ROA)?

Jasper Therapeutics, Inc. (JSPR) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jasper Therapeutics, Inc.'s P/E ratio?

Jasper Therapeutics, Inc. (JSPR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $19.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Jasper Therapeutics, Inc.'s price-to-sales ratio?

Jasper Therapeutics, Inc. (JSPR) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $19.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Jasper Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Jasper Therapeutics, Inc. (JSPR) held $28.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $77.2M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Jasper Therapeutics, Inc.'s Piotroski F-Score?

Jasper Therapeutics, Inc. (JSPR) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jasper Therapeutics, Inc.'s earnings high quality?

Jasper Therapeutics, Inc. (JSPR) reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.